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Stroke is the most debilitating cardiovascular event. It has a variety of causes that may be present simultaneously. In young or otherwise
healthy people, the search for a patent foramen ovale (PFO) has become standard. In stroke of the elderly, atherosclerosis and atrial ﬁbril-
lation are in the foreground but the PFO should not be ignored. The risk of a PFO-related stroke over time is controversial and so is its
prevention by device closure. The association of proximal aortic plaques in arteries subtending the brain and stroke is considered strong,
ignoring that it is as putative as that of the PFO. Statins can prevent progression of such plaques. Antiplatelet agents in asymptomatic
and surgical endarterectomy in symptomatic patients or highly ulcerated lesions are the treatment of choice. Stenting with protection
devices was shown competitive in selected patients.
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Introduction
Strokeisadevastatingeventandremainsasthethirdleadingcauseof
mortality and the most important cause of serious, long-term
disability.
1 Most strokes are of ischaemic origin. Atherosclerosis
plays a causative role as do other factors that vary among countries,
genders, lifestyles, and a number of well-documented risk factors.
2
In the USA, it is estimated that almost 90% of the roughly 800 000
strokes per year are ischaemic.
3 Cardioembolic reasons account
for 19% and carotid disease for 15% of those. A patent foramen
ovale (PFO) is per se not yet considered a primary cause for
stroke. It is subsumed under the  40% labelled cryptogenic. This
paper deals with the stroke causes that are easiest to document
and treat in the sense of primary and secondary prevention.
Patent foramen ovale
Autopsy studies revealed that the foramen ovale remains dynamic-
ally patent in approximately one-fourth of the general population.
4
The PFO thus represents the most common cardiac congenital
abnormality (Figure 1). It permits intracardiac shunting while right
atrial pressure exceeds left atrial pressure (Figure 2). The PFO
accounts for up to 95% of right-to-left shunts. Pulmonary shunts
account for about 4%, and atrial septal defects for less than 1%.
The prevalence of PFO declines from 34% during the ﬁrst three
decades to 25% for the fourth to eighth decade, and to 20%
beyond that.
4 Spontaneous closure even late in life or selective
mortality (reduced life expectancy of PFO carriers) have to be
accountable. In most individuals, a PFO will remain asymptomatic
for life. However, since the initial link of a fatal stroke in a young
woman to a PFO by Cohnheim in 1877, PFO and atrial septal
aneurysm (ASA) have been increasingly recognized as potential
mediators of systemic embolism.
ASA is a congenital abnormality of the interatrial septum charac-
terizedbyaredundant,centralpartoftheseptumprimum(Figure3).
The prevalence of ASA in the general population was about 1% in
autopsy series
5–7 and 2.2% in a population-based transoesophageal
echocardiographic (TOE) study.
8 ASA is associated with a PFO in
50–85% of cases
7–9 and likely co-responsible for it. The constant
motion of the ASA renders postnatal fusion difﬁcult and thus
begetsPFOs.Thecriteriafordistinction betweenaﬂoppyinteratrial
septum and ASA vary between autopsy, transthoracic
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7
ASA has been associated with cerebral ischaemic events in
numerous case–control studies.
7–13 The combination of PFO
and ASA must account for this and constitutes a particularly high-
risk situation with a relative risk of 16 (95% CI 3–86) comparing
ischaemic stroke with non-stroke control subjects, and a relative
risk of 17 (95% CI 2–134) comparing cryptogenic stroke with
known stroke cause control subjects (age ,55 years).
14 ASA
may facilitate paradoxical embolism by leading to a more frequent
and wider opening of the PFO channel
15 or by promoting a
right-to-left shunt by redirecting ﬂow from the inferior vena cava
towards the PFO.
16
Patent foramen ovale and stroke
In younger patients, a classical aetiology is not found in up to 40%
of ischaemic strokes despite an extensive diagnostic evaluation.
17,18
Such strokes are then referred to as cryptogenic, a misnomer in
the presence of a PFO. Despite the prevalence of around 25%
of a PFO in the general population,
4 paradoxical embolism is
rare and typically assumed rather than proved.
19 However, this
holds true equally for strokes attributed to atrial ﬁbrillation,
prior myocardial infarction, or proximal arterial plaques.
The association of PFO with cryptogenic stroke, reported in
1988,
20,21 as well as numerous case reports depicting a thrombus
straddling the PFO establish paradoxical embolism as underlying
mechanism. This is corroborated by an observational study of
139 patients suffering from major pulmonary embolism.
22 Patients
with PFO were more likely to die (44 vs. 13%, P ¼ 0.02) and to
suffer from stroke (13 vs. 2%, P ¼ 0.02) or peripheral embolism
(15 vs. 0%, P ¼ 0.01) with the presence of a PFO emerging as an
independent predictor of mortality. The higher frequency of
pelvic vein thrombosis at magnetic resonance (MR) venograms
within 2 days of the onset of symptoms in stroke patients with
PFO (20%) than with conventional stroke causes (4%) again
points to paradoxical embolism via PFO.
23 So do an observational
study of 202 patients with transvenous pacing leads, in whom the
presence of intracardiac shunts was associated with a .2-fold
increased risk of systemic embolism during long-term follow-up,
24
and a large Danish population-based study on patients with deep
venous thrombosis (n ¼ 25 199) or pulmonary embolism (n ¼ 16
925). Their relative risks of stroke during the ﬁrst year after the
thrombotic event were 2.2 (1.9–2.6) and 2.9 (2.3–3.7) fold
increased compared with controls (N ¼ 163 566).
25
Patent foramen ovale and ﬁrst ischaemic
stroke
In the European population, the annual incidence of a ﬁrst ischae-
mic stroke is 139 per 100 000 inhabitants.
26 Since around 60% of
these events can be attributed to conventional causes,
17,18 the
annual risk attributed to paradoxical embolism has been estimated
at 28 per 100000 persons with PFO per year.
27 The association of
PFO with cryptogenic stroke has been repeatedly conﬁrmed.
14,28
More recently, this observation has been extended to adults
.55 years, with a signiﬁcantly higher prevalence of PFO alone
(28.3 vs. 11.9%; OR 2.9; 95% CI 1.7–5.0; P , 0.001) as well as
Figure 1 Patentforamenovale(PFO)seenfromtherightatrium.
The caudal membranous septum primum approaches the cranial
muscular septum secundum, thereby closing the PFO.
Figure 2 Angiographic lateral view of a patent foramen ovale
showing contrast medium injected into the right atrium (RA)
passing (arrow) through the patent foramen ovale between the
thick septum secundum (SS) and the thin mobile septum
primum (SP) into the left atrium (LA). C, catheter; PA, pulmonary
artery; RV, right ventricle.
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8.5; P , 0.001) among patients with cryptogenic stroke compared
with those with conventional stroke causes.
29 A recent
meta-analysis of 23 case–control studies
30 suggested that the
odds of PFO were 2.9 times higher in patients with cryptogenic
stroke when compared with controls (95% CI 2.1–4.0).
In contrast, two prospective population-based studies failed to
conﬁrm PFO as an independent risk factor for cryptogenic
stroke,
31,32 with only an insigniﬁcant trend towards a higher inci-
dence of stroke in persons with PFO. The Olmsted County
Study enrolled 588 randomly selected subjects.
31 PFO was identi-
ﬁed using TTE in 24% and an ASA in 2%. During a mean follow-up
of 5.1 years, cerebrovascular events (cerebrovascular death,
ischaemic stroke, and TIA) occurred in 41 subjects (7%). After
adjustment for age and co-morbidities, PFO was not an independ-
ent predictor of stroke (hazard ratio, HR 1.46; 95% CI 0.74–2.88;
P ¼ 0.28). The risk of stroke among subjects with ASA was almost
four times greater than that in those without, but proportional
hazard regression analysis did not establish statistical signiﬁcance
(HR 3.72; 95% CI 0.88–15.71; P ¼ 0.074). The relatively small
sample size and the advanced age (mean 67 years) of the study par-
ticipants were criticised, in addition to the inadequate screening
sensitivity resulting in a signiﬁcant percentage of undetected PFOs.
Among the 1100 participants of the Northern Manhattan
Study,
32 TTE detected a PFO in only 15% and an ASA in 3%.
During 6.6 years of follow-up, 68 subjects suffered an ischaemic
stroke (6%). After adjustment for demographic and risk factors,
PFO was not signiﬁcantly associated with stroke (HR 1.64; 95%
CI 0.87–3.09). Isolated ASA was associated with an elevated
stroke incidence (HR 3.66; 95% CI 0.88–15.30), but ASA
associated with PFO was not (HR 1.25; 95% CI 0.17–9.24). The
low prevalence of PFO when compared with autopsy studies
again unmasks TTE as not sensitive enough to screen for PFO.
Patent foramen ovale and recurrent
cerebrovascular events
The natural history after cerebrovascular events in patients with
PFO remains insufﬁciently deﬁned, which is problematic since
the risk of recurrence determines the therapeutic value of inter-
ventions aimed at secondary prevention. Traditionally, most
patients with presumed paradoxical embolism were treated with
antithrombotic medications. Data are scarce concerning the efﬁ-
cacy of oral anticoagulation as opposed to antiplatelet agents and
the duration of treatment required. Observational studies on
medical treatment in patients with PFO with either antiplatelet
agents or coumarin reported a risk of recurrent stroke or TIA
ranging from 3 to 12% during the ﬁrst year.
9,12,16,28,33,34 Both
larger PFO size
15,18,35,36 and a greater degree of right-to-left
shunt
15,16,35,37 signify a higher risk for paradoxical embolism.
However, there are major differences in the baseline characteris-
tics of the patient populations studied, which may account for
the disparate recurrence rates reported. According to a recent
meta-analysis of 15 studies of medical treatment in 2548 patients
with cryptogenic cerebrovascular events, the pooled rate of recur-
rent ischaemic stroke or TIA was 4.0 events per 100 patient-years
(95% CI 3.0–5.1) while the rate of recurrent ischaemic stroke was
1.6 events per 100 patient-years (95% CI 1.1–2.1).
38 Of note, in
trials with antiplatelet agents or oral anticoagulation, the risk of
recurrence appeared lower with the latter. Current medical
Figure 3 Patent foramen ovale (PFO) associated with an atrial septal aneurysm (ASA) depicted by transoesophageal echocardiography (left
panel) and angiography (right panel). The atrial septal aneurysm bulges into the left atrium (LA) after a sustained Valsalva manoeuvre allowing
for a shunt into the left atrium (LA). The inset shows the situation after PFO closure with a 25 mm Amplatzer PFO occluder.
Secondary stroke prevention 707treatment recommendations are mainly based on one randomized
clinical trial with blinded outcome assessment, the Patent foramen
ovale In Cryptogenic Stroke Study (PICSS),
28 and three prospect-
ive studies.
9,16,33
Althoughmedicaltreatmentlackstheriskofinterventionalproce-
dures, it is associated with other adverse effects, most notably an
increased risk of bleeding. Thus, major bleeding amounted to
1.5–2.2per100patient-yearsintheprospectivePICSS
28anditssub-
analysis, the Warfarin-Aspirin Recurrent Stroke Study (WARSS),
39
with no signiﬁcant differences between acetylsalicylic acid and oral
anticoagulation. Treatment with acetylsalicylic acid has been found
insufﬁcient in patients with PFO and associated ASA.
9,12 Another
important limitation of medical treatment is lack of compliance.
Percutaneous patent foramen ovale
closure
Percutaneous (device) closure of the PFO has supplanted surgical
PFO closure and constitutes an alternative treatment. It eliminates
the pathway for paradoxical embolism and may thus circumvent
the need for long-term blood thinners. However, it is associated
with a small periprocedural risk and signiﬁcant cost.
Bridges et al.
40 introduced percutaneous PFO closure in 1992 to
reduce the incidence of recurrent strokes. Since then, percutan-
eous PFO closure has been shown safe and feasible in numerous
studies, using a variety of devices (Figure 4).
41–52 The reported
success rates varied between 90 and 100%, with complication
rates between 0 and 10%. Complete PFO closure was reported
in 51–100% of patients, and yearly recurrence rates of ischaemic
strokes and TIAs varied between 0 and 3.4%.
All patients should undergo TOE prior to the intervention for
initial diagnosis of PFO and detailed delineation of anatomy (i.e.
associated ASA, Eustachian valve; Figures 3 and 5) including assess-
ment of right-to-left shunt. The procedure can be performed on an
outpatient basis under local anaesthesia and may take less than
30 min.
52 Patients can be released to unrestricted physical activity
as early as a few hours after the intervention. Antibiotics during the
intervention are commonplace and prevention against endocarditis
is recommended for a few months until the device is completely
covered by tissue. Failed implantation due to inability to canulate
the PFO is extremely rare (,1%). Periprocedural complications
have fallen below 1% in experienced centres, and complete
closure rates of .90% can be expected.
52 Follow-up treatment
includes acetylsalicylic acid (80–300 mg daily) for 1–6 months,
Figure 4 Selection of clinically used closure devices for the patent foramen ovale. The device name is on top and the company name is inside
the respective pictures.
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some centres. At 3–6 months after percutaneous PFO closure, a
contrast TOE should be repeated, to assess for residual shunt fol-
lowing endothelial overgrowth and exclude thrombosis of the
device. Transcranial Doppler constitutes an alternative. However,
it cannot rule out a thrombus on the device. If the PFO proves
completely closed, all medication can be discontinued, unless
required for another indication, e.g. associated coronary artery
disease.
53 In case of persistence of a moderate or large residual
shunt, implantation of a second device is recommended, which
results in complete closure in  90% of cases.
52
Complications consist mostly of arteriovenous ﬁstulae at the
groin and are device- and technique-related.
41,51,54 The same
holds true for residual shunts and thrombus formation.
55 Erosion
of the free atrial wall, device endocarditis, or need for surgical
explantation are exceedingly rare. Long-term safety is of utmost
importance for a preventive procedure against a low risk in
natural history. Rarely, supraventricular arrhythmias can be
induced or triggered by the device leading to need for anticoagula-
tion or left atrial ablation. Transseptal puncture (for later left atrial
interventions) is rather optically guided and not impeded after
device implantation (Figure 6).
Comparison of medical treatment with
patent foramen ovale closure
Available evidence of studies assessing medical treatment and
percutaneous PFO closure encompass multiple observational
single-arm studies, two comparative registries,
56,57 and a systematic
review of case series.
58 None of the prospective, randomized clin-
ical trials has been published to date. Oral presentation of the
CLOSURE I trial (Prospective, Multicenter, Randomized
Controlled Trial to Evaluate the Safety and Efﬁcacy of the STAR-
Flex Septal Closure System Versus Best Medical Therapy in
Patients with a Stroke of Transient Ischemic Attack due to Pre-
sumed Paradoxical Embolism through a Patent Foramen Ovale)
showed no signiﬁcant advantage of PFO closure with the obsolete
STARFlex device at 2 years of follow-up. Wo ¨hrle
58 recently sum-
marized clinical outcomes from 8 studies comprising 998 medically
treated patients and 12 studies with 2016 patients who underwent
percutaneous PFO closure. The annual rate of stroke or TIA was
signiﬁcantly lower after percutaneous PFO closure (1.3%, 95% CI
1.0–1.8) compared with medical treatment (5.2%, 95% CI 4.4–
6.2) and was comparable to event rates of patients without PFO.
PercutaneousPFOclosuremaybeparticularlyvaluableinpatients
with PFO and associated ASA. One study compared clinical out-
comes following device closure between patients with both PFO
and ASA (n ¼ 141) and those with PFO alone (n ¼ 220).
41 Device
implantation success and the rate of residual shunt assessed by
Figure 5 Angiographic (left panel) and transoesophageal view (right panel) of a patent foramen ovale (PFO) associated with an Eustachian
valve (EV) channelling the inﬂow from the inferior vena cava (IVC) directly onto the PFO. The left panel shows a catheter in the IVC and a
25 mm Amplatzer PFO occluder in the PFO. LA, left atrium; RA, right atrium.
Figure 6 Ideal projection and area (dotted line) of transseptal
puncture after patent foramen ovale closure.
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groups. At 4 years of follow-up, the rate of recurrent stroke, TIA,
or peripheral embolism amounted to 5.1 and 6.0% in patients with
and without ASA, respectively (HR ¼ 0.8, 95% CI 0.3–2.3, P ¼
0.70). Accordingly, device closure in patients with both PFO and
ASA lowered the rate of recurrence to that of patients with PFO
alone, which was considerably lower than the 19.2% rate reported
in the French PFO/ASA study.
9
However, the results of the above-mentioned studies have to be
interpreted in light of limitations of non-randomized registries with
unmeasured characteristics, lack of data monitoring, and independ-
ent event adjudication, and variations in deﬁnitions, outcome
measures, and their assessment.
Current state of the subject
Despite growing recognition of the PFO, particularly when asso-
ciated with an ASA, as risk factor for several disease manifestations,
theoptimaltreatmentstrategyforpatientswithdocumentedorsus-
pected paradoxical embolism remains controversial. Percutaneous
PFO closure is a minimally invasive procedure which can be per-
formed with high success and low morbidity. With respect to
secondary prevention of recurrent embolic events, percutaneous
PFO closure appears to be clinically at least as effective as medical
treatment.
56,58However,ithastobeemphasizedthatthetruethera-
peuticefﬁcacyofpercutaneousPFOclosureasadjunctoralternative
to medicaltreatment canonlybeascertainedwithlong-termrando-
mized studies. The ﬁrst such trial (CLOSURE I) showed no beneﬁt
but was limited to 2 years of follow-up and used a device sincewith-
drawn. The Patent foramen ovale for Cryptogenic stroke (PC), the
Randomised Evaluation of recurrent Stroke comparing PFO
closure to Established Current standard of care Treatment
(RESPECT), the Gore Helex Septal Occluder and Antiplatelet
Medical Management for Reduction of Recurrent Stroke or
Imaging-Conﬁrmed TIA in Patients with Patent Foramen Ovale
(REDUCE), and the Patent Foramen Ovale Closure or Anticoagu-
lants Versus Antiplatelet Therapy to Prevent Stroke Recurrence
(CLOSE) trials are ongoing. Enrollment is slow and skewed as
most patients believed to be at high risk undergo percutaneous
PFO closure. Due to lower-than expected event rates, the included
patient numbers and follow-up duration risk to be insufﬁcient to
achievesatisfactorypower.Besides,strokepathophysiologyismulti-
factorial,andthediagnosisofPFO-mediatedparadoxicalembolismis
presumptive. Both a PFO and a cryptogenic stroke may coexist
without causal relation in a given patient. In this case, PFO closure
will not reduce the risk of recurrence.
30 Notwithstanding, non-
randomizedstudiesshowaconsistent patterninfavourofpercutan-
eous PFO closure in all-comers. At least patients with multiple
embolic events warrant percutaneous PFO closure,
56 especially if
they already failed medical treatment.
Aortic plaques
It is controversial whether aortic plaques are a risk factor for
stroke, a marker for generalized atherosclerosis, or a harmless inci-
dental ﬁnding. Due to this uncertainty and the lack of evidence-
based data to support speciﬁc drug therapy in patients with
stroke and aortic plaques, clinicians face a dilemma in choosing
proper secondary prophylaxis in patients with TIA or ischaemic
stroke and aortic plaques on echocardiography.
Many retrospective case–control studies have reported a strong
association between aortic atheromas and stroke.
59–61 Independ-
ent of other traditional atherosclerotic risk factors, the incidence
of atheromatous plaques involving the thoracic aorta was consist-
ently higher in patients with cerebral embolism compared with
control groups. As studies were of retrospective nature, true
cause-and-effect relationship could not be established. Subse-
quently, several prospective follow-up studies have shown an asso-
ciation between aortic plaques and stroke.
62,63 The risk of embolic
stroke from aortic atheromatous plaque varies with different
plaque morphology. Complex plaques, which are deﬁned by the
presence of protruding atheroma of more than 4 mm thickness,
mobile debris, or plaque ulceration, are more likely to embolize
than simple plaques. Lack of calciﬁcation independently increases
the embolic risk.
64 The suspected reason might be that non-
calciﬁed plaques are lipid-laden and prone to rupture and
thrombosis.
Recent community-based studies found no association between
aorticatheromaandfuturestroke.InaprospectivestudyofMeissner
et al.,
65 581 participants of the Stroke Prevention Assessment of
Risk in a Community (SPARC) study were followed for vascular
events. In their observation, both simple and complex atheroma-
tous plaques were not an independent predictor of either
cardiac events or strokes. In a case–control analysis of Petty
et al.,
66 the prevalence of ascending and thoracic aortic atheroma
among the SPARC participants (random controls) compared
with three other groups—patients with cryptogenic stroke,
patients with stroke attributed to another aetiology, and patients
undergoing TOE for non-neurological indications (referred
controls)—was not signiﬁcantly associated with group status.
Based on these results, the authors concluded that aortic
atheroma was not a risk factor for cryptogenic stroke.
Russo et al.
67 prospectively evaluated prevalence of aortic
plaques and risk of vascular events and ischaemic stroke associated
with plaques in the aortic arch or in the proximal portion of the
descending aorta in 209 stroke-free subjects from the Aortic
Plaques and Risk of Ischemic Stroke (APRIS) study. Large plaques
in the aortic arch were not associated with an increased risk of
vascular events over a 6-year follow-up, whereas plaques in the
proximal descending aorta were associated with an increased
risk of combined events in unadjusted analyses, but not after
adjustment for other risk factors. The authors concluded that
this observation may suggest that plaques in the descending
aorta represent rather a marker of atherosclerosis than a direct
cause for the events.
In contrast, Harloff et al.
68,69 postulated that complex plaques of
the aorta displayed an embolic high-risk source for stroke. By
multidirectional-dimensional (3D) velocity mapping, they could
prove the connection of complex plaques of the descending
aorta with supra-aortic vessels that supplied the territory of
visible acute and embolic retinal or cerebral infarction by retro-
grade ﬂow. In a prospective study including 94 stroke patients,
time-resolved 3D MR could explain potential embolization from
the descending aorta in 19 of 57 patients (33.3%) with determined
stroke aetiology and in 9 of 37 patients (24.3%) with cryptogenic
B. Meier et al. 710stroke. However, the true incidence and clinical relevance of this
mechanism remains unclear.
Apart from the fact that the real impact of aortic plaques on the
aetiology of ischaemic stroke is still unsolved, optimal treatment
strategies for patients with aortic atheromatous plaques are not
well deﬁned.
Statins
Statins seem to be a sensible concept in patients with aortic
plaques because of their pleiotropic effects. Beyond lipid lowering,
statins attenuate plaque inﬂammation, reduce endothelial dysfunc-
tion, and have antithrombotic properties.
70 Aortic plaque regres-
sion during statin therapy has been reported through the use of
MR monitoring.
71 Therapy for 6 months led to signiﬁcant aortic
plaque regression and reverse remodelling which was strongly
associated with low-density lipoprotein cholesterol reduction. In
a randomized trial with either simvastatin or diet alone, Tahara
et al.
72 observed patients who underwent ﬂuorodeoxy glucose
(FDG) positron emission tomography scan for cancer screening
and were found to have increased FDG uptake in the thoracic
aorta or carotid artery. After 3 months, simvastatin reduced
plaque inﬂammation signiﬁcantly when compared with diet alone.
However, these two studies did not monitor cerebrovascular end-
points. Independent from the use of statins in patients with aortic
plaque, pravastatin has been found to reduce the incidence of
stroke in patients with coronary artery disease.
73,74 In an observa-
tional study of 519 patients followed for 3 years with severe aortic
arch plaque, multivariate analysis showed that statin therapy was
independently protective against recurrent events (number
needed to treat ¼ 6).
75 No protective effect was found for the
use of warfarin or antiplatelet drugs.
Anticoagulation and antiplatelet drugs
As unstable aortic plaques are associated with intravascular throm-
bus embolization, anticoagulation with warfarin has been used for
primary or secondary prophylaxis in patients with aortic plaque.
Although three non-randomized observational trials showed ben-
eﬁts of anticoagulation with warfarin,
76–78 others did not.
75,79 In
a retrospective observational trial with 129 patients by Ferrari
et al.,
77 patients with complex plaques showed a decreased inci-
dence of vascular events and death under treatment with oral
anticoagulation when compared with antiplatelet therapy. In
contrast, Tunick et al.
75 found no signiﬁcant beneﬁt of warfarin
or antiplatelet drugs on the incidence of stroke and other
embolic events in 519 patients with severe thoracic aortic
plaque. The French study of aortic plaques in stroke reported
similar results.
80 In WARSS, a recent double-blind randomized
trial, therapy with warfarin or acetylsalicylic acid was compared
in 516 patients with ischaemic stroke.
79 Endpoints were recurrent
ischaemic stroke or death over a 2-year follow-up period. Especial-
ly large plaques were associated with a signiﬁcantly increased risk
of events, but no interaction was observed between warfarin treat-
ment and large plaques on the risk of events. In all these studies,
the effect of statin therapy, which could improve aortic plaque
stability, was not measured. As outlined above, this could act as
a confounding factor and the actual effects of either anticoagulation
or antiplatelet drugs could be underestimated or exaggerated.
Besides, the use of dual antiplatelet therapy is not reported. The
ongoing Aortic arch Related Cerebral Hazard (ARCH) trial,
comparing warfarin and clopidogrel plus acetylsalicylic acid, may
be the next step towards evidence-based data to secondary
prevention in patients with aortic plaque. Future studies should
also evaluate the value of newer, safer agents like direct thrombin
inhibitors in this indication.
Surgery
Aortic arch endarterectomy during coronary artery bypass grafting
has been suggested for aortic atheromatous disease.
81 As intrao-
perative stroke rate is very high and long-term anticoagulation
with warfarin and regular surveillance with TOE or MR are neces-
sary because of increased risk of recurrence, surgery should only
be considered in desperate cases of young patients with recurrent
emboli, despite maximal medical treatment.
Current state of the subject
Although a retrospective study indicated a likely beneﬁt from
statins, the best medical treatment for patients with aortic
plaque has not yet been determined. Statins are recommended
in any patient with atherosclerosis, as these drugs have been
shown to reduce the risk of stroke and myocardial infarction and
have plaque stabilization properties. As unstable aortic plaques
may develop superimposed thrombi, seen as mobile elements on
TOE, anticoagulation with warfarin may be a reasonable therapy.
Antiplatelet drugs have not been proved to be beneﬁcial in patients
with aortic plaques and ischaemic stroke. However, until a proper
randomized control trial is done, oral anticoagulation cannot be
deﬁnitely recommended.
Carotid stenosis
Surgery vs. stenting
Two large randomized trials, the North American Symptomatic
Carotid Endarterectomy Trial (NASCET) and the European
Carotid Surgery Trial (ESC), found a clear beneﬁt for carotid
endarterectomy compared with medical treatment in patients
with high-degree symptomatic stenosis of the internal carotid
artery (ICA).
82,83 Taken together, the trials found an absolute
risk reduction of 13.5% over 5 years for the combined endpoint
of stroke and death in favour of carotid endarterectomy.
84 The
risk reduction was even higher in patients with an ICA stenosis
.90%. In patients with an ICA stenosis of 50–69%, the 5-year
absolute risk reduction for the endpoint ipsilateral stroke was
4.6%. Patients with an ICA stenosis ,50% did not beneﬁt from
carotid endarterectomy. The short-term complication rates
(stroke and death) were 6.2% with an ICA stenosis .70 and
8.4% with an ICA stenosis of 50–69%. One should, however,
keep in mind that these studies were performed at times when
optimal treatment of vascular risk factors was not available.
Soon after balloon dilatation and stenting had been introduced
in cardiology, these methods were applied in patients with signiﬁ-
cant carotid stenosis without scientiﬁc proof of efﬁcacy or super-
iority over carotid endarterectomy.
85,86 The following section
reports the results of the recently published randomized trials
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and asymptomatic carotid stenosis (Table 1).
87–92
SPACE (Stent-protected Percutaneous Angioplasty of the
Carotid vs. Endarterectomy) randomized 1200 symptomatic
patients with a .50% stenosis (according to the NASCET criteria)
or .70% (according to ESC criteria) to carotid endarterectomy or
stenting within 6 months after a TIA or minor stroke.
89 The
primary endpoint, ipsilateral stroke, or death within 30 days
occurred in 6.84% of patients undergoing stenting and 6.34% of
patients undergoing carotid endarterectomy. A post-hoc subgroup
analysis identiﬁed age ,68 years as a factor being associated
with a lower complication rate in patients treated with stenting.
The complication rate of surgery was not age-dependent.
93 In
this study, the use of a protection system did not inﬂuence the
complication rate. In the SAPPHIRE study, enrolling high-risk
patients, complication rates were even slightly lower with carotid
stenting than with carotid endarterectomy (Table 1).
88 In contrast,
the EVA-3S (Endarterectomy Versus Angioplasty in Patients with
Severe Symptomatic Carotid Stenosis) was terminated premature-
ly after 527 patients were randomized due to a signiﬁcant differ-
ence in the 30-day complication rate favouring carotid surgery
(9.6 vs. 3.9%; OR 2.5; 95% CI 1.25–4.93).
90 Of note, however,
EVA-3S involved a considerable number of centres with very
limited experience in carotid stenting which makes the interpret-
ation of this study difﬁcult. In addition, the complication rate of
surgery was much lower than that observed in the SPACE study.
The International Carotid Stenting Study (ICSS) randomized
1713 patients (stenting group, n ¼ 855; endarterectomy group,
n ¼ 858).
91 Between randomization and 120 days, there were 34
(4.0%) events of disabling stroke or death in the stenting group
compared with 27 (3.2%) events in the endarterectomy group
(HR 1.28). The incidence of stroke, death, or procedural myocar-
dial infarction was 8.5% (72) in the stenting group compared with
5.2% (44) in the endarterectomy group (HR 1.69, P ¼ 0.006). Any
stroke (65 vs. 35 events; HR 1.92) and all-cause death (19 vs. 7
events; HR 2.76) were more frequent in the stenting group than
in the endarterectomy group.
CREST randomly assigned patients with symptomatic or asymp-
tomatic carotid stenosis to carotid-artery stenting or carotid
endarterectomy.
92 The primary composite endpoint was stroke,
myocardial infarction, or death from any cause during the peripro-
cedural period (30 days) or any ipsilateral stroke within 4 years
after randomization of 2502 patients observed over 2.5 years.
There was no signiﬁcant difference in the estimated 4-year rates
of the primary endpoint between the stenting group and the
endarterectomy group (7.2 and 6.8%, respectively; HR 1.11, P ¼
0.51). The 4-year rate of stroke or death was 6.4% with stenting
and 4.7% with endarterectomy (HR 1.50, P ¼ 0.03). The rates
among symptomatic patients were higher than among asymptom-
atic patients, but in both groups there was no difference in out-
comes between surgery and stenting. Periprocedural
complications differed between the stenting group and the
endarterectomy group (death: 0.7 vs. 0.3%, P ¼ 0.18; stroke: 4.1
vs. 2.3%, P ¼ 0.01 and myocardial infarction: 1.1 vs. 2.3%, P ¼ 0.03).
A meta-analysis included 11 randomized trials (but not CREST)
and reported outcomes in 4796 patients.
84 The periprocedural risk
of stroke or death was lower for carotid surgery (OR 0.67, P ¼
0.025) than for carotid stenting. The risk of myocardial infarction
(OR 2.69, P ¼ 0.036) and cranial nerve injury (OR 10.2, P ,
0.001) was higher in patients undergoing carotid endarterectomy.
Taken together, the results of the so far published studies show
a lower and in some cases a similar complication rate for endarter-
ectomy compared with carotid stenting. The reported medium-
time outcomes in a 2–4-year follow-up were comparable but
the restenosis rate was higher after carotid stenting.
95,96 It is
likely that the success of carotid stenting (and for that matter
also of carotid endarterectomy) depends heavily on the experi-
ence of a given centre.
There remain many unanswered research questions despite the
12 studies published so far. Most of the studies were underpow-
ered to show non-inferiority or equivalence of carotid stenting
compared with endarterectomy. In addition, the trials had different
primary and secondary endpoints and different deﬁnitions for com-
plications. Some studies included only patients with symptomatic
..................................... ..................................... .....................................
...............................................................................................................................................................................
Table 1 Risk of stroke or death from large-scale randomized trials comparing endovascular carotid artery stenting
(CAS) and surgical carotid endarterectomy (CEA) treatment in patients with severe carotid-artery stenosis
Patients Any stroke or death at 30
days
Disabling stroke or death at
30 days
Ipsilateral stroke after 30
days
CAS (n, %) CEA (n,%) CA S(n,%) CEA (n,%) CAS (n,%) CEA (n,% )
CAVATAS
87 504 25 (10.0) 25 (9.9) 16 (6.4) 15 (5.9) 6
a 10
a
SAPPHIRE
88 334 8 (4.8) 9 (5.4) n.a. n.a. n.a. n.a.
SPACE
89 1214 46 (7.7) 38 (6.5) 29 (4.8) 23 (3.9) 4 (0.7)
b 1 (0.2)
b
EVA 3S
90 527 25 (9.6) 10 (3.9) 9 (3.4) 4 (1.5) 2 (0.6)
b 1 (0.3)
b
ICSS
c91 1713 72 (8.5) 40 (4.7) 34 (4.0) 27 (3.0) 58 (6,8) 30 (3.5)
CREST
92 2502 55 (6.8) 29 (3.6) n.a. n.a. n.a. n.a.
n.a. ¼ not available).
aFollow-up duration 1.95 years in mean.
bFollow-up duration up to 6 months.
cOutcome at 90 days (intention-to-treat data).
B. Meier et al. 712carotid stenosis, whereas others had a mixture of symptomatic and
asymptomatic patients. There seems to be an age effect on out-
comes. Patients aged over 70–75 years had a higher early compli-
cation rate with carotid stenting while the rate in carotid
endarterectomy was not age-dependent. None of the trials consid-
ered plaque morphology. One would expect that carotid stenosis
with a heavy calciﬁcation load would beneﬁt more from endarter-
ectomy than from stenting.
Current state of the subject
Symptomatic patients with signiﬁcant stenosis of the ICA should
preferably undergo carotid endarterectomy. In experienced
centres, carotid stenting can be equivalent in terms of beneﬁt
and complications. The beneﬁt of surgery is no longer present
when the complication rate exceeds 6%.
96 Most of the randomized
studies, however, achieved complication rates below that. There-
fore, patient selection is of major importance. In addition, one
has to consider the countries in which the trials were performed.
For patients enrolled in the USA (CREST) or Germany, Austria,
and Switzerland (SPACE), carotid surgery and carotid stenting
seem to be similar. Therefore, experience and complication rate
of a particular vascular surgeon, interventionalist, or team may
decide which method is preferred.
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